Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Long-Term Debt Repayments (2018 - 2025)

Guided Therapeutics' Long-Term Debt Repayments history spans 8 years, with the latest figure at $94000.0 for Q3 2025.

  • For Q3 2025, Long-Term Debt Repayments rose 74.07% year-over-year to $94000.0; the TTM value through Sep 2025 reached $511000.0, up 79.93%, while the annual FY2024 figure was $438000.0, 6.31% up from the prior year.
  • Long-Term Debt Repayments for Q3 2025 was $94000.0 at Guided Therapeutics, up from $71000.0 in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $811000.0 in Q2 2021 and bottomed at $41000.0 in Q2 2023.
  • The 5-year median for Long-Term Debt Repayments is $94000.0 (2025), against an average of $180588.2.
  • The largest annual shift saw Long-Term Debt Repayments tumbled 94.7% in 2022 before it soared 342.22% in 2024.
  • A 5-year view of Long-Term Debt Repayments shows it stood at $811000.0 in 2021, then tumbled by 90.75% to $75000.0 in 2022, then tumbled by 40.0% to $45000.0 in 2023, then skyrocketed by 342.22% to $199000.0 in 2024, then plummeted by 52.76% to $94000.0 in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Long-Term Debt Repayments are $94000.0 (Q3 2025), $71000.0 (Q2 2025), and $147000.0 (Q1 2025).